Diabetes, Heart Disease, Fatty Liver, Blood Groups and COVID-19 Disease: A Brief Review of Evidences

Journal Title: Journal of Quality in Health Care & Economics (JQHE) - Year 2021, Vol 4, Issue 3

Abstract

SARS-CoV-2 infection can have a severe evolution and complications in people who present comorbidities. Indeed, people with diabetes, especially those with type 1, and COVID19 are exposed to and an increased risk of diabetic ketoacidosis. Also cardiac complications due to coronary heart disease or other cardiovascular one, such as hypertension, are possible. These complications may be caused by the virus entering into cardiomyocytes or even other surrounding cells. In people with fatty liver/hepatic impairment and COVID-19, there is an increased expression of ACE2 receptors through the HEK293 cell line, which allows SARS-CoV-2 to enter the cells through the TMPRSS2 interface with the help of the regulatory protein PIKFYE, by therefore increasing the severity of the disease. Moreover SARS-CoV-2 after entry causes T-cell CD8 + reaction, which leads to liver cell damage. The incidence of COVID-19 seems to be high in people with blood group A and low in those with blood group 0. For these reason, the aim of this review is to summarize evidence of main metabolic comorbidities (diabetes, cardiovascular diseases, and liver diseases) and blood groups and COVID-19.

Authors and Affiliations

Yavari M, Afshar MM, Jabalameli F, kharkani PS, Jafari NM, kharkani SS, Eskandarian Z, Kamyar G, Esmaeili H* and Ahmadzada M

Keywords

Related Articles

Health in All Policies: Management Model for the Comprehensive Transformation of the System

The essay explores the components of the approach health in all policies as a management model based on primary health care and its basic principles for health promotion described in the Ottawa Charter and the Adelaide...

The Role of Maternity Services in Reducing the Prevalence and Cost of Perinatal Depression and Anxiety during COVID-19 in England

In 2020 the novel coronavirus outbreak (COVID-19) was declared a global pandemic. Pregnant women have been recognised as a group specifically at risk during this time due to the impact that the COVID-19 infection may ha...

Postgraduate Course: Smoking Vs. Labor Productivity

Background: Smoking is close related with no-communicable illness. As consequence from the smoking impact over morbidity and mortality smokers laboring reduces the self labor productivity agree to tobacco consumption. T...

Health Care Ethics Informed Consent, Quality of Life, and Full Disclosure

Health care ethics have taken an importance not appreciated in times past as a person’s individual wishes are emphasized and respected more robustly in the 21st century. A patient has the individual right to decide his/...

Performance Evaluation on Science and Innovation Management Process in A Cuban Medical University

Quality represents a form of management focused and concerned on user satisfaction, as well as processes and results improvement. In an institution like the university, quality must involve all academic and administrati...

Download PDF file
  • EP ID EP751122
  • DOI 10.23880/jqhe-16000225
  • Views 21
  • Downloads 0

How To Cite

Yavari M, Afshar MM, Jabalameli F, kharkani PS, Jafari NM, kharkani SS, Eskandarian Z, Kamyar G, Esmaeili H* and Ahmadzada M (2021). Diabetes, Heart Disease, Fatty Liver, Blood Groups and COVID-19 Disease: A Brief Review of Evidences. Journal of Quality in Health Care & Economics (JQHE), 4(3), -. https://europub.co.uk/articles/-A-751122